You are here

  • Home
  • Archive
  • Volume 80, Issue 11
  • Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial

Article metrics

Article menu
Download PDFPDF
Rheumatoid arthritis
Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial

 

Online download statistics by month:

Online download statistics by month: April 2021 to March 2024

AbstractFullPdf
Apr 20215702412
May 20211470221292
Jun 2021897595
Jul 2021685746
Aug 2021786838
Sep 2021634847
Oct 2021134213985
Nov 20218349986
Dec 20215806363
Jan 20223976040
Feb 20223364021
Mar 20224746661
Apr 20223443630
May 20223953324
Jun 20225354725
Jul 20223434739
Aug 20224805531
Sep 20225093219
Oct 20223813727
Nov 20224445329
Dec 2022266158
Jan 20234293620
Feb 20232864421
Mar 20233194319
Apr 20233793013
May 20233332713
Jun 20233212124
Jul 20233333223
Aug 20232042017
Sep 20232012223
Oct 20231791913
Nov 20232072212
Dec 20231322217
Jan 20242221616
Feb 202423299
Mar 20242072016
Total1398216981374